Impact of Endotest on Patients' Quality of Life: a Cohort Study
Key facts
- Where
- Bordeaux, Lorient, Montivilliers, Pau, Peltre, Saint-Grégoire, and Saint-Priest-en-Jarez, FranceSee the 7 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 43 years old?
Source: NCT07560852, who can take part
Where in France
- Clinique Tivoli-DucosBordeaux, FranceTaking people
- Groupe Hospitalier Bretagne Sud - GHBS - LorientLorient, FranceNot yet recruiting
- Hôpital Jacques Monod - GH du HavreMontivilliers, FranceNot yet recruiting
- Centre Hospitalier de PauPau, FranceNot yet recruiting
- Hôpital de Mercy - CHR Metz ThionvillePeltre, FranceNot yet recruiting
- Hopital Privé Saint GrégoireSaint-Grégoire, FranceNot yet recruiting
- Chu de Saint EtienneSaint-Priest-en-Jarez, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- ZIWIG
- Trial code
- NCT07560852
- Record updated
- 26 May 2026
- Original description
Ziwig Endotest® ('Endotest') is marketed in several countries, including Switzerland, which was the first country to make it available in 2022. Since February 2025, several French clinical investigation sites have been offering Endotest, developed by Ziwig, under the innovation funding. Initially, this innovation funding enabled 2,500 patients to be included in a clinical trial (ENDOBEST: ID-RCB 2024-A02092-45). Since the end of December 2025, it has been expanded and now covers a further 22,500 patients whose are not included in the trial. This medical device is based on Next-Generation Sequencing combined with analytical algorithms and enables the identification of endometriosis from a saliva sample. This non-invasive test aims to improve patient care by reducing diagnostic delays and guiding treatment strategies.Read full original descriptionShow less
Ziwig Endotest® ('Endotest') is marketed in several countries, including Switzerland, which was the first country to make it available in 2022. Since February 2025, several French clinical investigation sites have been offering Endotest, developed by Ziwig, under the innovation funding. Initially, this innovation funding enabled 2,500 patients to be included in a clinical trial (ENDOBEST: ID-RCB 2024-A02092-45). Since the end of December 2025, it has been expanded and now covers a further 22,500 patients whose are not included in the trial. This medical device is based on Next-Generation Sequencing combined with analytical algorithms and enables the identification of endometriosis from a saliva sample. This non-invasive test aims to improve patient care by reducing diagnostic delays and guiding treatment strategies.
Despite the available data on its diagnostic performance, the impact of Endotest on patients' quality of life, their emotional experience, their coping strategies, and their care pathways remains insufficiently documented. Indeed, the Endotest result (positive or negative) can significantly influence these various aspects. This cohort study aims to assess the impact of Endotest on patients' quality of life, primarily using validated self-report questionnaires and clinical data from medical records. By including a large sample of patients, this study aims to provide robust and generalisable data that will be useful for clinicians and patients themselves.
Inclusion: Women with a prescription for Endotest; Women aged 18 to 43; Who have dated and signed the consent form; Affiliated with the French healthcare system or covered by health insurance abroad.
Exclusion: Contraindications for the use of Endotest:; Current pregnancy; Medical history of cancer or HIV infection; Active infection at the time of saliva collection; Significant difficulty reading and understanding the language of the country in which the participant is located.